Targeting the Leading Cause of Death in Friedreich’s Ataxia with a Gene Therapy

R. Nolan Townsend, CEO of Lexeo Therapeutics, discusses Friedreich’s ataxia, his company’s gene therapy in development, and its pursuit of gene therapies for both rare and common diseases.